ArticlePatient education and counseling2016
Treatment recommendations by clinicians in stage I non-small cell lung cancer: A study of factors that influence the likelihood of accounting for the patient's preference.
Article in Patient education and counseling, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Specific risks and outcomes of octogenarians post-lung cancer resection: our 5-year experience.Journal of thoracic disease · 2024Article
- Stereotactic ablative radiotherapy (SABR) for patients with lung tumor and severe pulmonary function impairment.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Propensity score-based analysis of stereotactic body radiotherapy, lobectomy and sublobar resection for stage I non-small cell lung cancer.Journal of radiation research · 2022Article
- Information, deliberation, and decisional control preferences for participation in medical decision-making and its influencing factors among Chinese cancer patients.Health expectations : an international journal of public participation in health care and health policy · 2021Article
- Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach.The oncologist · 2021Review
- The Value of Hope: Patients' and Physicians' Preferences for Survival in Advanced Non-Small Cell Lung Cancer.Patient preference and adherence · 2020Article
- Treatment recommendations by clinicians in stage I non-small cell lung cancer: better work-up leads to less discussion.Annals of translational medicine · 2017Article
- Treatment recommendations for stage I non-small cell lung cancer: does patient preference matter?Annals of translational medicine · 2017Article
- Shared decision making in the treatment of stage I non small cell lung cancer-a choice which should equally involve both sides.Annals of translational medicine · 2017Article
- A Review of Shared Decision-Making and Patient Decision Aids in Radiation Oncology.Journal of cancer education : the official journal of the American Association for Cancer Education · 2017Review
- Development and implementation of the lung volume reduction pulmonary rehabilitation tool to identify eligibility for lung volume reduction in people with chronic obstructive pulmonary disease during pulmonary rehabilitation.Chronic respiratory diseaseObservational
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSurgery and stereotactic ablative radiotherapy (SABR) are both curative treatment options for patients with stage I non-small cell lung cancer (NSCLC). Shared decision making (SDM) has been advocated in this patient group. This study explored clinician decision making in relation to the stated treatment preferences of patients.
methodsIn a previous study, we conducted a binary choice experiment with hypothetical cases among 126 clinicians. Secondary data analysis was performed using multilevel logistic regression models, in which random differences between clinicians' decisions were taken into account. We analyzed the influence of patient- and clinician-related characteristics, and uncertainty as experienced by clinicians about their recommendation on the clinician's decision (either in line with the patient's preference or not).
resultsSignificant interactions were observed between patient- and clinician-related characteristics, indicating that patient preferences were selectively taken into account, depending on clinicians' specialty, their views about the comparability of cancer-related outcomes following surgery and SABR, and the degree of uncertainty about the treatment recommendation.
conclusionsOur findings suggest that SDM for stage I NSCLC care is largely influenced by how clinicians weigh available scientific evidence. PRACTICE IMPLICATIONS: Clinicians should involve lung cancer patients more and ask for their preferences in making treatment recommendations.
Indexed as
Identifiers
27372523What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.